SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

ANG Lifesciences - Quaterly Results

14 Aug 2024 Evaluate
The Sales for the quarter ended June 2024 of Rs. 161.77 million declined by -68.03% from Rs. 506.08 millions.The Net Loss for the quarter ended June 2024 is Rs. -27.66 millions as compared to Net Profit of Rs. 15.97 millions of corresponding quarter ended June 2023Operating profit Margin for the quarter ended June 2024 slipped to -5.69% as compared to 60.12% of corresponding quarter ended June 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 161.77 506.08 -68.03 161.77 506.08 -68.03 1313.69 2070.05 -36.54
Other Income 13.58 3.43 295.92 13.58 3.43 295.92 8.35 98.42 -91.52
PBIDT -5.69 60.12 -109.46 -5.69 60.12 -109.46 99.51 209.10 -52.41
Interest 16.69 19.38 -13.88 16.69 19.38 -13.88 93.28 103.24 -9.65
PBDT -22.38 40.74 -154.93 -22.38 40.74 -154.93 -11.12 105.86 -110.50
Depreciation 15.11 19.36 -21.95 15.11 19.36 -21.95 77.55 85.16 -8.94
PBT -37.49 21.38 -275.35 -37.49 21.38 -275.35 -88.67 20.70 -528.36
TAX -9.83 5.41 -281.70 -9.83 5.41 -281.70 -2.19 27.31 -108.02
Deferred Tax -9.83 -2.78 253.60 -9.83 -2.78 253.60 -2.21 6.23 -135.47
PAT -27.66 15.97 -273.20 -27.66 15.97 -273.20 -86.48 -6.61 1208.32
Equity 130.58 130.58 0.00 130.58 130.58 0.00 130.58 130.58 0.00
PBIDTM(%) -3.52 11.88 -129.61 -3.52 11.88 -129.61 7.57 10.10 -25.01

ANG Lifesciences Share Price

26.10 -0.46 (-1.73%)
21-Apr-2026 13:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1674.00
Dr. Reddys Lab 1221.00
Cipla 1230.55
Zydus Lifesciences 930.45
Lupin 2323.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×